- Home
- WM vs SNY Comparison
WM vs SNY Comparison
Compare WM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WM | SNY |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3B | 119.4B |
| IPO Year | 1988 | N/A |
Fundamental Metrics
Financial Performance| Metric | WM | SNY |
|---|---|---|
| Price | $226.14 | $46.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 6 |
| Target Price | ★ $250.32 | $61.50 |
| AVG Volume (30 Days) | 1.7M | ★ 2.8M |
| Earning Date | 01-28-2026 | 01-29-2026 |
| Dividend Yield | 1.49% | ★ 3.50% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 6.35 | ★ 8.67 |
| Revenue | $24,784,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $18.09 | $1.73 |
| Revenue Next Year | $5.48 | $6.49 |
| P/E Ratio | $34.85 | ★ $5.27 |
| Revenue Growth | ★ 15.88 | N/A |
| 52 Week Low | $194.11 | $44.62 |
| 52 Week High | $242.58 | $60.12 |
Technical Indicators
Market Signals| Indicator | WM | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 38.07 |
| Support Level | $214.84 | $45.25 |
| Resistance Level | $222.27 | $48.17 |
| Average True Range (ATR) | 3.66 | 0.71 |
| MACD | 0.30 | -0.19 |
| Stochastic Oscillator | 99.91 | 24.21 |
Price Performance
Historical ComparisonAbout WM Waste Management Inc.
WM ranks as the largest integrated provider of traditional solid waste and medical waste services in the United States, operating 262 active landfills, about 506 solid and medical waste transfer stations, and 105 recycling facilities. The company serves residential, commercial, industrial, and medical end markets and is also a leading recycler in North America.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.